HDAC6 (Redirect)

HDAC6

Pathway Diagram

Overview

Histone Deacetylase 6 (HDAC6) is a class IIb histone deacetylase (HDAC) enzyme encoded by the HDAC6 gene located on the X chromosome in humans. Unlike most HDACs that function primarily in the nucleus, HDAC6 is predominantly cytoplasmic and exhibits unique substrate specificity that extends beyond histones to include non-histone proteins. HDAC6 contains two tandem catalytic domains and a zinc finger-like ubiquitin-binding domain (ZnF UBD), which distinguishes it from other HDAC family members. This distinctive structural architecture enables HDAC6 to function as a key regulator of protein quality control, cellular stress responses, and cytoskeletal dynamics—processes increasingly recognized as fundamental to neurodegeneration.

Function/Biology

HDAC6

Pathway Diagram

Overview

Histone Deacetylase 6 (HDAC6) is a class IIb histone deacetylase (HDAC) enzyme encoded by the HDAC6 gene located on the X chromosome in humans. Unlike most HDACs that function primarily in the nucleus, HDAC6 is predominantly cytoplasmic and exhibits unique substrate specificity that extends beyond histones to include non-histone proteins. HDAC6 contains two tandem catalytic domains and a zinc finger-like ubiquitin-binding domain (ZnF UBD), which distinguishes it from other HDAC family members. This distinctive structural architecture enables HDAC6 to function as a key regulator of protein quality control, cellular stress responses, and cytoskeletal dynamics—processes increasingly recognized as fundamental to neurodegeneration.

Function/Biology

HDAC6 catalyzes the removal of acetyl groups from lysine residues on target proteins, thereby regulating their biological activity and cellular localization. The enzyme's primary substrates include α-tubulin and heat shock protein 90 (Hsp90), though it also deacetylates aggresome proteins and other cytoplasmic targets. Through its ubiquitin-binding domain, HDAC6 physically associates with polyubiquitinated protein aggregates and mediates their transport along microtubules to aggresomes—cellular compartments specialized for storage and degradation of misfolded proteins.

The deacetylation of α-tubulin reduces microtubule stability and promotes dynein-mediated transport toward minus ends of microtubules, facilitating aggresome formation. Additionally, HDAC6 regulates Hsp90 acetylation status, influencing the chaperone's ability to stabilize client proteins involved in cellular signaling. HDAC6 also participates in autophagy regulation, linking protein quality control mechanisms with lysosomal degradation pathways. The enzyme's activity is modulated by post-translational modifications and binding partners, allowing for dynamic responses to cellular stress conditions.

Role in Neurodegeneration

HDAC6 dysfunction is implicated across multiple neurodegenerative diseases characterized by protein misfolding and aggregation. In Huntington's disease (HD), mutant huntingtin (mHtt) protein forms cytoplasmic inclusions; HDAC6 overexpression enhances clearance of these aggregates through improved autophagy and aggresome formation. Conversely, HDAC6 inhibition in HD models can exacerbate neuronal toxicity by impairing quality control mechanisms.

In Alzheimer's disease (AD), HDAC6 levels are altered in affected brain regions, and dysregulation of HDAC6-mediated autophagy contributes to accumulation of amyloid-β and phosphorylated tau. Similarly, in Parkinson's disease (PD), HDAC6 modulation affects α-synuclein aggregation and clearance, with reduced HDAC6 activity correlating with enhanced neuronal vulnerability to α-synuclein toxicity. In amyotrophic lateral sclerosis (ALS), HDAC6 dysfunction impairs clearance of misfolded TDP-43 and FUS proteins, contributing to motor neuron degeneration.

Molecular Mechanisms

HDAC6 regulates neurodegeneration through multiple interconnected mechanisms. First, the enzyme controls protein aggregation dynamics by regulating microtubule acetylation status, which determines trafficking capacity for misfolded proteins. Second, HDAC6-mediated deacetylation of autophagy-related proteins (including ATG proteins) modulates autophagic flux, allowing selective clearance of pathogenic aggregates. Third, through Hsp90 deacetylation, HDAC6 influences the stability of neurodegeneration-associated proteins including tau kinases and α-synuclein-interacting factors.

Additionally, HDAC6 participates in immune responses to neurodegeneration; its activity in microglia and astrocytes affects neuroinflammatory cytokine production. The enzyme also regulates mitochondrial dynamics and trafficking through acetylation-dependent mechanisms, affecting bioenergetic stress responses critical to neuronal survival.

Clinical/Research Significance

HDAC6 inhibitors represent promising therapeutic candidates for neurodegenerative diseases. Selective HDAC6 inhibitors (such as tubacin and more advanced compounds) enhance protein clearance and reduce neuronal toxicity in multiple disease models without significantly affecting histone acetylation or gene expression changes associated with pan-HDAC inhibition. Clinical trials investigating HDAC6-selective inhibitors for HD and other polyglutamine diseases are underway, with preclinical data suggesting benefits in enhancing aggregate clearance and preserving motor function.

The enzyme's role in balancing protein quality control suggests combination therapies pairing HDAC6 modulation with autophagy enhancers or proteasome-targeted approaches may optimize therapeutic efficacy.

Related Entities

• HDAC family proteins (HDAC1-11)
• α-tubulin and microtubule dynamics
• Heat shock proteins (Hsp70, Hsp90)
• **